- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Acadia adds pain meds to the pipeline with $52.5M CerSci buyout | ||
| Di | Medtronic reports 44% drop in quarterly income as it begins to recover from COVID-19 | ||
| Di | Takeda, Ovid rare epilepsy drug slashes seizures in phase 2 | ||
| Di | Qiagen to launch digital, portable test for COVID-19 antibodies, preordering 900K for U.S. | ||
| Di | Science 37 teams up with ERT to tap into high-quality data from virtual trials | ||
| Di | Tricida sinks as FDA rejection raises prospect of new trial | ||
| Di | AstraZeneca starts phase 1 of antibodies that could protect against COVID-19 for 6 months | ||
| Di | Connect Biopharma adds $115M to the pot as it eyes rivalry with Dupixent | ||
| Di | AbbVie pulls the trigger on Morphic fibrosis programs, adding $20M to deal | ||
| Mo | Novartis' PD-1 combo flops in phase 3 melanoma test | ||
| Mo | Bionano Genomics acquires pediatric neurodevelopment testing company Lineagen | ||
| Mo | Yumanity backs onto Wall Street via Proteostasis merger | ||
| Mo | Trump pushes for preelection fast-tracked approval of AstraZeneca COVID-19 vaccine: report | ||
| Mo | Functioning liver cells regenerate in pig lymph nodes, and a human trial is coming | ||
| Mo | Bristol Myers to buy Forbius in hunt for Opdivo-enhancing drugs | ||
| Mo | Aslan hopes to roar again as Dupixent rival test resumes after COVID-19 chaos | ||
| Fr | FDA reports new cases of cancer, illnesses linked to breast implants | ||
| Fr | Trump administration revokes FDA authority over lab-developed tests, including some COVID-19 diagnostics | ||
| Fr | Lilly partner AbCellera adds bispecifics platform to antibody arsenal | ||
| Fr | MD Anderson's Hwu takes up vacant CEO post at scandal-hit Moffitt Cancer Center | ||
| Fr | Outsmarting COVID-19 and other viruses by analyzing RNA in single cells | ||
| Fr | Pfizer, BioNTech share clinical data linking favored COVID-19 vaccine to improved tolerability | ||
| Fr | Virtual FDA AdComm for Alkermes' ALKS 3831 adds new focus on drug-drug interactions | ||
| Fr | Astellas' Audentes reports 3rd death in gene therapy trial | ||
| Fr | Virtual trial specialist and Big Pharma-backed Science 37 nabs $40M funding round |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
